Last reviewed · How we verify
Losmapimod for repeat dose
At a glance
| Generic name | Losmapimod for repeat dose |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase I Study of GW856553 (Losmapimod) (PHASE1)
- A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Losmapimod for repeat dose CI brief — competitive landscape report
- Losmapimod for repeat dose updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI